Valuation dashboard for Immunovant, Inc. (IMVT) with P/E N/A, P/B 9.99, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Valuation Ratios
| Price / Book | 9.99 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $4.93 |
| vs Current Price | -86.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| PRAX | Praxis Precision Medicines, Inc. | $8.6B | 6.34 | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.5B | 5.45 | -29.8% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.7B | 12.24 | 3.62 | |
| DYN | Dyne Therapeutics, Inc. | $3.2B | 4.12 |
Price
| Price | $36.38 |
| Market Cap | $7.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 97.10% |
| Operating Margin | -7877.46% |
| Net Margin | -7585.86% |
Related companies: ACAD · AKRO · CRNX · DYN · KYMR · NAMS · PRAX
Explore sector: Healthcare · Biotechnology
More sections of IMVT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks